Changes in Velocimetric Indices of Uterine and Umbilical Arteries Before and After Combined Spinal-epidural Analgesia in Laboring Women

Combined spinal-epidural (CSE) for labor analgesia has been used for many years and is practiced commonly at our institution, especially when the patient requests immediate pain relief. CSE is not only beneficial for its faster onset of analgesia, but also it is favorable in relation to the need for rescue analgesia, urinary retention, and rate of instrumental delivery compared to the traditional epidural. Despite its beneficial effects, there is a risk of about 15-30% of developing abnormal fetal heart rate following CSE. This is self-resolving with minimal or no intervention. Although the cause of fetal bradycardia is not fully elucidated, variations in uterine artery blood flow after epidural analgesia are thought to be due to the interaction of numerous events related to blockade of sympathetic innervations, fluid administration, maternal hypotension, uterine vascular effects of sympathetic block, fluctuations in circulating catecholamines, and possibly the effect of opioids. Similar mechanism is thought to be a cause of fetal bradycardia after the CSE with its faster onset and superior block.

Maternal or fetal circulation during labor can be assessed using continuous-wave Doppler ultrasound to monitor maternal uterine artery (UtA) and fetal umbilical artery (UmA) velocity waveforms to detect changes in blood flow. The velocimetry indices mentioned above have been often used to assess the changes in the blood flow before and after the induction of epidural analgesia during labor in several studies. Although there are some studies regarding the effect of labor epidural analgesia using velocimetry indices, but there is currently no published study evaluating velocimetry indices of uterine and umbilical arteries before and after the induction of CSE. Thus, the aim of this study is to investigate the impact of CSE to maternal and fetal blood flow to evaluate the relationships.

The investigators hypothesize that both uterine artery and umbilical artery blood flow are reduced after the induction of CSE, which may be responsible for the occurrence of fetal bradycardia.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5G1X5
        • Mount Sinai Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Written informed consent
  • Term pregnant patients requesting labor analgesia
  • Singleton pregnancy
  • Term pregnant patients in active labor
  • ASA<4
  • No evidence of fetal congenital anomalies, fetal compromise or fetal decelerations prior to CSE

Exclusion Criteria:

  • Refusal to consent for the study
  • Known spinal deformities
  • Previous back instrumentation
  • Patients with BMI>50 kg/㎡ due to anticipated technical challenges in Doppler studies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ultrasound
Ultrasound will be used to measure velocimetric indices of both right and left uterine arteries and umbilical artery.
Ultrasound scan of the right and left uterine arteries and umbilical artery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Uterine artery velocimetric index - systolic/diastolic ratio (S/D) at baseline
Time Frame: 5 minutes
Uterine artery velocimetric index - systolic/diastolic ratio (S/D) will be measured at baseline (prior to combined spinal epidural).
5 minutes
Uterine artery velocimetric index - systolic/diastolic ratio (S/D) at 10 minutes
Time Frame: 5 minutes
Uterine artery velocimetric index - systolic/diastolic ratio (S/D) will be measured 10 minutes after combined spinal epidural
5 minutes
Uterine artery velocimetric index - systolic/diastolic ratio (S/D) at 30 minutes
Time Frame: 5 minutes
Uterine artery velocimetric index - systolic/diastolic ratio (S/D) will be measured 30 minutes after combined spinal epidural
5 minutes
Uterine artery velocimetric index - pulsatility index (PI) at baseline
Time Frame: 5 minutes
Uterine artery velocimetric index - pulsatility index (PI) will be measured at baseline (prior to combined spinal epidural).
5 minutes
Uterine artery velocimetric index - pulsatility index (PI) at 10 minutes
Time Frame: 5 minutes
Uterine artery velocimetric index - pulsatility index (PI) will be measured 10 minutes after combined spinal epidural
5 minutes
Uterine artery velocimetric index - pulsatility index (PI) at 30 minutes
Time Frame: 5 minutes
Uterine artery velocimetric index - pulsatility index (PI) will be measured 30 minutes after combined spinal epidural
5 minutes
Uterine artery velocimetric index - resistance index (RI) at baseline
Time Frame: 5 minutes
Uterine artery velocimetric index - resistance index (PI) will be measured at baseline (prior to combined spinal epidural).
5 minutes
Uterine artery velocimetric index - resistance index (RI) at 10 minutes
Time Frame: 5 minutes
Uterine artery velocimetric index - resistance index (PI) will be measured 10 minutes after combined spinal epidural
5 minutes
Uterine artery velocimetric index - resistance index (RI) at 30 minutes
Time Frame: 5 minutes
Uterine artery velocimetric index - resistance index (PI) will be measured 30 minutes after combined spinal epidural
5 minutes
Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) at baseline
Time Frame: 5 minutes
Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) will be measured at baseline (prior to combined spinal epidural).
5 minutes
Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) at 10 minutes
Time Frame: 5 minutes
Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) will be measured 10 minutes after combined spinal epidural
5 minutes
Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) at 30 minutes
Time Frame: 5 minutes
Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) will be measured 30 minutes after combined spinal epidural
5 minutes
Umbilical artery velocimetric index - pulsatility index (PI) at baseline
Time Frame: 5 minutes
Umbilical artery velocimetric index - pulsatility index (PI) will be measured at baseline (prior to combined spinal epidural).
5 minutes
Umbilical artery velocimetric index - pulsatility index (PI) at 10 minutes
Time Frame: 5 minutes
Umbilical artery velocimetric index - pulsatility index (PI) will be measured 10 minutes after combined spinal epidural
5 minutes
Umbilical artery velocimetric index - pulsatility index (PI) at 30 minutes
Time Frame: 5 minutes
Umbilical artery velocimetric index - pulsatility index (PI) will be measured 30 minutes after combined spinal epidural
5 minutes
Umbilical artery velocimetric index - resistance index (PI) at baseline
Time Frame: 5 minutes
Umbilical artery velocimetric index - resistance index (PI) will be measured at baseline (prior to combined spinal epidural).
5 minutes
Umbilical artery velocimetric index - resistance index (PI) at 10 minutes
Time Frame: 5 minutes
Umbilical artery velocimetric index - resistance index (PI) will be measured 10 minutes after combined spinal epidural
5 minutes
Umbilical artery velocimetric index - resistance index (PI) at 30 minutes
Time Frame: 5 minutes
Umbilical artery velocimetric index - resistance index (PI) will be measured 30 minutes after combined spinal epidural
5 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain score at baseline - questionnaire
Time Frame: 1 minute
Pain score - verbal numeric rating scale (0-10) prior to combined spinal epidural
1 minute
Pain score at 10 min - questionnaire
Time Frame: 1 minute
Pain score - verbal numeric rating scale (0-10) at 10 min after combined spinal epidural
1 minute
Pain score at 30 min - questionnaire
Time Frame: 1 minute
Pain score - verbal numeric rating scale (0-10) at 30 min after combined spinal epidural
1 minute
Hypotension: systolic blood pressure less than 80% of baseline
Time Frame: 30 minutes
Systolic blood pressure < 80% of baseline, monitored q5 for 30 minutes following combined spinal epidural
30 minutes
Hypertension: systolic blood pressure greater than 120% of baseline
Time Frame: 30 minutes
Systolic blood pressure > 120% of baseline, monitored q5 for 30 minutes following combined spinal epidural
30 minutes
Bradycardia: heart rate less than 70% of baseline
Time Frame: 30 minutes
Heart rate < 70% of baseline or a heart rate < 50bpm, monitored q5 for 30 minutes following combined spinal epidural
30 minutes
Desaturation: oxygen level <95%
Time Frame: 30 minutes
Oxygen level <95%, monitored q5 for 30 minutes following combined spinal epidural
30 minutes
Sensory block level at 10 minutes
Time Frame: 10 minutes
Sensory block level at 10 minutes following combined spinal epidural
10 minutes
Sensory block level at 30 minutes
Time Frame: 30 minutes
Sensory block level at 30 minutes following combined spinal epidural
30 minutes
Duration of labour
Time Frame: up to 24 hours
Onset of labour until delivery of the placenta
up to 24 hours
Type of delivery
Time Frame: up to 24 hours
Type of delivery will be recorded: vaginal, cesarean section, instrumental delivery
up to 24 hours
Presence of hypertonic uterine contractions
Time Frame: up to 24 hours
Presence of hypertonic uterine contractions as noted by the nursing or obstetric team.
up to 24 hours
fetal heart rate at baseline
Time Frame: 5 minutes
fetal heart rate at baseline, prior to combined spinal epidural
5 minutes
fetal heart rate q5 min up to 30 minutes
Time Frame: 30 minutes
fetal heart rate q5 min up to 30 minutes following combined spinal epidural
30 minutes
presence of fetal bradycardia - questionnaire
Time Frame: up to 24 hours
presence of fetal bradycardia (fetal heart rate <110)
up to 24 hours
presence of fetal tachycardia - questionnaire
Time Frame: up to 24 hours
presence of fetal tachycardia (fetal heart rate >160)
up to 24 hours
Neonatal weight
Time Frame: 2 minutes
Neonatal weight measured after delivery in grams
2 minutes
Apgar score at 1 minute
Time Frame: 1 minute
Apgar score at 1 minute
1 minute
Apgar score at 5 minutes
Time Frame: 5 minute2
Apgar score at 5 minutes
5 minute2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mrinalini Balki, MD, Mount Sinai Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 14, 2022

Primary Completion (Actual)

March 30, 2024

Study Completion (Actual)

March 30, 2024

Study Registration Dates

First Submitted

August 19, 2022

First Submitted That Met QC Criteria

August 19, 2022

First Posted (Actual)

August 23, 2022

Study Record Updates

Last Update Posted (Actual)

October 24, 2024

Last Update Submitted That Met QC Criteria

October 22, 2024

Last Verified

October 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 22-04

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Labor Pain

Clinical Trials on Ultrasound

Subscribe